Where indicated, human cells were stimulated in the presence of human IFN-α (1000 U/ml; PBL Biomedical Laboratories, Piscataway, NJ) and rhesus cells with universal type I IFN (1000 U/ml; PBL Biomedical Laboratories). To support viability in the rhesus B-cell cultures, IL-2 (100 ng/ml, PeproTech, Rocky Hill, NJ) and B-cell activation Seliciclib cost factor of the tumour necrosis factor family (BAFF; 100 ng/ml, PeproTech) were added to the rhesus cultures in the experiments where differentiation and antibody

production were measured. Human and rhesus PBMCs were labelled with 0·25 μm CFSE (Molecular Probes, Eugene, OR) for 7 min at 37° and thoroughly washed with complete medium as described elsewhere.2,3 Using the conditions described above 2 × 106 cells/ml were cultured at 37° in polystyrene round-bottom tubes in complete medium. TLR ligands were used at 1 μg/ml (Poly I:C and TLR7/8-L) and 5 μg/ml (CpG classes), optimal concentrations of each ligand that caused peak B-cell activation. Proliferation was measured by flow cytometry and data were analysed using FlowJo software. Live cells were gated on by exclusion of propidium iodide staining. B cells were gated based on expression of CD20 and CD19 for rhesus and human B cells, respectively, and lack of CD3 and CD14. Alternatively, proliferation was measured

selleck chemicals by thymidine incorporation where PBMCs or B cells were cultured in 96-well plates and pulsed with [3H]thymidine (1 μCi/well, Amersham Bioscience, GE Healthcare Biosciences AB, Uppsala, Sweden) for 16 hr after 4 days of culture. The level of incorporation mafosfamide of [3H]thymidine was measured by a 1450 MicroBeta PLUS counter (Wallac, PerkinElmer Sverige AB, Upplands Väsby, Sweden) and expressed as counts per minute (c.p.m.). Human or rhesus PBMCs at 6 × 106 cells/ml

were exposed to the TLR7/8-L (1 μg/ml) or CpG ODN class C (5 μg/ml) for 1 hr at 37° in polystyrene round-bottom tubes, followed by an additional 10 hr in the presence of the secretion inhibitor Brefeldin A (10 μg/ml; Sigma-Aldrich) and then stained as described previously.33,34 Briefly, the cells were fixed and permeabilized for 15 min using a BD Cytofix/Cytoperm kit (BD Pharmingen). The cells were then washed twice and stained with antibodies specific for IFN-α (clone MMHA-11, PBL Biomedical Laboratories), CD3, CD14, CD20, CD123, HLA-DR (antibodies as described above). The cells were analysed by flow cytometry. In addition, IFN-α levels in the supernatants of cells exposed for 24 hr to the TLR ligands were measured by ELISA (Mabtech, Stockholm, Sweden) performed according to the manufacturer’s instructions. Phenotypic differentiation of B cells was assessed for up to 6 days of culture by flow cytometry using antibodies against CD20, CD27, IgG and IgM (all BD Pharmingen). Expression of IgG and IgM was assessed by intracellular staining using the BD Cytofix/Cytoperm kit before staining.